🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Vertex Pharmaceuticals Incorporated VRTX NDXSPX

Healthcare · Biotechnology · United States
https://www.vrtx.com
Company Profile ↓
$477.08
+1.00% 1Y
Mkt Cap$121.09B
P/E28.33
P/B6.92
52W High$529.59
52W Low$366.54
Book Value$76.18
EPS (TTM)$16.84

Company Overview

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.4%.

Steady Revenue Expansion

Revenue has grown at a 10.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 35.5%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.10.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $12.00B (+8.9% YoY); net profit $3.95B.
  • Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings +61.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 6.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.35%
1 Year:7.80%

Compounded Profit Growth

5 Years:5.97%
1 Year:61.40%

Stock Price Performance

1 Year:+1.00%
6 Months:+3.58%
3 Months:+7.38%
1 Month:+7.23%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 68% of range
$366.54 $529.59
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)49.17 · Neutral
Price Performance
1M+7.23%
3M+7.38%
6M+3.58%
1Y+1.00%
Valuation vs Sector

P/E of 28.33 is above the sector median of 25.88 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.2%.
  • Healthy ROCE of 21.4%.
  • Excellent profit margin of 35.5%.
  • Compounding revenue at 10.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
28.33
Industry PE
25.88
Forward P/E
22.22
PEG Ratio
1.96
Book Value
$76.18
Price to Book
6.92
P/S
10.95
EV/EBITDA
25.85
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
10.35%
Profit 5Y
5.97%
Revenue (YoY)
7.80%
Earnings (YoY)
61.40%

Profitability & Returns

ROCE
21.38%
ROE
24.20%
ROA
12.14%
Profit Margin
35.51%
Op Margin
38.13%
Gross Margin
54.39%
EPS (Latest Qtr)
$4.02
EPS (TTM)
$16.84

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
2.38
Current Ratio
3.02
Debt
$1.99B
Total Assets
$26.48B
Current Assets
$11.73B
Working Capital
$7.34B

Ownership

Promoter Holding
0.20%
Chg in Prom Hold
-0.00%
FII / Inst Holding
97.95%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$121.09B
Total Revenue (TTM)
$12.22B
EBITDA
$4.98B
Free Cash Flow
$2.78B
Operating Cash Flow
$4.24B
Shares Outstanding
253.81M
Gross Margin
54.39%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VRTX Vertex Pharmaceuticals Incorporated NDXSPX 477.08 28.33 $121.09B 0.00% 21.38% 24.20% 10.35% 5.97%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------714.72M544.13M578.16M651.63M640.80M752.16M784.53M870.11M858.43M941.29M949.83M1.41B1.52B1.52B1.54B1.63B1.72B1.79B1.98B2.10B2.20B2.33B2.37B2.49B2.48B2.69B2.65B2.77B-2.77B2.96B3.08B3.19B2.99B
Cost of Revenue -----------------------------------363.00M407.50M414.80M466.00M392.80M
Gross Profit -----------------------------------2.41B2.56B2.66B2.72B2.59B
Operating Expenses -----------------------------------1.38B1.40B1.42B1.59B1.46B
Operating Income -70.03M-53.70M-14.33M3.35M-18.73M39.64M270.84M52.71M-326.04M125.74M128.90M172.88M205.65M127.72M276.81M269.96M99.33M551.47M720.22M718.03M672.24M745.79M887.80M-37.90M1.05B1.04B1.11B1.13B779.00M1.03B1.04B1.14B-3.51B1.12B-1.03B1.15B1.24B1.13B1.14B
EBITDA -----------------------------------1.08B1.34B1.36B1.39B1.19B
Interest Expense ----------------------------------2.80M3.00M3.70M3.30M3.30M-
Pretax Income -----------------------------------730.40M1.28B1.30B1.33B1.25B
Tax Provision -----------------------------------84.10M250.10M215.90M139.90M221.50M
Net Income -95.15M-73.73M-41.63M-64.53M-38.84M32.95M247.76M18.00M-102.95M100.68M210.26M207.36M128.75M1.55B268.63M267.43M57.52M583.23M602.75M837.27M667.43M604.19M653.10M67.00M851.90M762.10M810.50M930.50M699.80M915.70M1.04B1.10B-3.59B1.05B-646.30M1.03B1.08B1.19B1.03B
Diluted EPS -0.39--0.17-0.26-0.160.130.990.07-0.410.390.810.800.505.971.031.030.222.232.293.182.532.302.490.263.282.963.133.592.693.523.974.21-13.924.01-2.493.994.204.654.02
R&D Expense 246.28M310.18M255.86M271.01M272.37M248.45M273.56M289.45M454.95M306.66M310.55M337.53M330.51M437.88M339.49M379.09M555.95M480.01M448.53M420.93M493.50M466.58M456.00M1.41B493.75M603.10M--------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 175.50M101.89M143.37M1.41B1.53B1.21B580.41M1.03B1.70B2.49B3.05B4.16B6.21B-8.93B9.87B11.02B12.00B
Cost of Revenue --------------1.08B1.26B1.53B1.65B
Gross Profit --------------7.85B8.61B9.49B10.35B
Operating Expenses --------------3.60B4.83B9.72B5.80B
Operating Income -462.71M-614.01M-696.08M113.82M46.73M-610.01M-692.41M-466.88M9.94M123.24M635.15M1.20B2.86B-4.25B3.78B-233.40M4.55B
EBITDA --------------4.44B4.61B486.30M4.87B
Interest Expense --------------54.80M44.10M30.60M13.30M
Pretax Income --------------4.23B4.38B248.50M4.64B
Tax Provision --------------910.40M760.20M784.10M690.00M
Net Income --642.18M-754.63M29.57M-107.03M-445.03M-738.55M-556.33M-112.05M263.48M2.10B1.18B2.71B-3.32B3.62B-535.60M3.95B
Diluted EPS -3.27-3.71-3.770.14-0.50-1.98-3.14-2.31-0.461.048.094.5110.29-12.8213.89-2.0815.32
R&D Expense 516.91M550.27M637.42M707.71M765.90M882.10M855.51M995.92M1.05B1.32B1.42B1.75B1.83B3.05B----

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.96B1.73B2.20B2.76B2.32B2.33B2.50B2.90B3.55B3.56B6.25B6.26B8.32B11.75B13.43B18.15B22.73B22.53B25.64B
Current Assets -----------------13.23B14.14B9.60B11.20B
Cash & Equivalents 355.66M389.12M446.66M243.20M475.32M489.41M569.30M625.26M714.77M1.18B1.67B-2.65B-3.11B5.99B6.79B10.50B10.37B4.57B5.08B
Inventory -----------------460.60M738.80M1.21B1.69B
Receivables -----------------1.44B1.56B1.61B2.05B
Total Liabilities --859.14M1.22B1.24B1.52B962.64M1.24B1.40B1.56B1.50B-1.81B-2.23B3.06B3.33B4.24B5.15B6.12B6.98B
Current Liabilities --284.88M474.78M392.35M432.62M397.83M368.25M506.17M792.54M807.26M-1.12B-1.33B1.88B2.14B2.74B3.55B3.56B3.86B
Long Term Debt ---------------------
Total Debt -----------------899.70M808.40M1.74B2.03B
Total Equity 271.30M238.87M1.10B503.97M786.84M999.18M1.36B1.08B939.97M1.16B2.03B-4.44B-6.09B8.69B10.10B13.91B17.58B16.41B18.67B
Shares Outstanding -----------------257.01M257.70M256.94M253.99M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -226.48M-427.59M-635.44M143.74M267.84M-60.67M-573.11M-365.43M236.10M844.94M1.27B1.57B3.25B-4.13B3.54B-492.60M3.63B
Investing Cash Flow -360.65M-508.73M7.30M----268.86M51.24M-483.33M-202.16M-1.24B99.40M--321.10M-3.14B-3.77B-945.40M
Financing Cash Flow 620.74M999.01M425.06M----188.92M133.27M68.40M-71.22M126.80M-505.30M--67.70M-562.20M-1.49B-2.26B
Capital Expenditure -32.18M-23.50M-38.05M-34.59M-71.14M-51.39M-51.20M-45.30M-56.56M-99.42M-95.45M-75.40M-259.80M--204.70M-258.40M-485.40M-437.60M
Free Cash Flow -258.66M-451.08M-673.50M109.14M196.70M-112.06M-624.31M-410.73M179.54M745.52M1.17B1.49B2.99B-3.93B3.28B-978.00M3.19B
Net Change in Cash --------------3.74B-166.60M-5.76B424.70M
Share Buybacks --------00350.04M186.00M539.10M1.43B0427.60M1.18B2.02B

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------87.9%87.2%86.1%86.2%
Operating Margin % -263.6%-602.6%-485.5%8.1%3.1%-50.3%-119.3%-45.2%0.6%5.0%20.8%28.8%46.0%-47.6%38.3%-2.1%37.9%
Net Margin % --630.3%-526.3%2.1%-7.0%-36.7%-127.2%-53.9%-6.6%10.6%68.8%28.3%43.7%-37.2%36.7%-4.9%32.9%
ROE % --58.6%-149.7%3.8%-10.7%-32.8%-68.7%-59.2%-9.7%13.0%47.3%19.3%31.2%-23.9%20.6%-3.3%21.2%
ROCE % --36.8%-55.7%6.3%2.0%-31.8%-35.2%-23.4%0.5%4.5%12.4%17.1%28.9%-27.6%19.7%-1.2%20.9%

Shareholding Pattern

Insiders
0.20%
Institutions
97.95%
Public Float
98.15%

Top Institutional Holders

#Holder% HeldSharesValue
1 Capital World Investors 10.00% 25.37M $12.07B
2 Blackrock Inc. 9.44% 23.97M $11.41B
3 Capital Research Global Investors 8.32% 21.13M $10.05B
4 Vanguard Capital Management LLC 6.51% 16.51M $7.86B
5 State Street Corporation 4.62% 11.73M $5.58B
6 JPMORGAN CHASE & CO 2.77% 7.03M $3.35B
7 Geode Capital Management, LLC 2.42% 6.14M $2.92B
8 Vanguard Portfolio Management LLC 2.03% 5.15M $2.45B
9 Capital International Investors 2.02% 5.13M $2.44B
10 LOOMIS SAYLES & CO L P 1.58% 4.00M $1.91B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VRTX

Google News Wed, 15 Jul 2026

Vertex Pharmaceuticals Stock Slides 10% Over 6 Straight Down Days - Trefis

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbDVXM0xSMWZVMGozVFQwOE5idmx4Z1ZZckFIQXBKMTZVRDFPei1oTUJOZkJCbjRoZzJGczFfdGFTMzRvR0NSa2R1eXpyX29CR1dZWFc4XzZmYnNGbWhWLWFIVkdEUGgtZUdIaUxmOUl3UlllQnNYcHROUmtPeTZTSjJZcm02V1ZYX0JxZH…

Google News ue, 23 Jun 2026

Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPNzJydi1RUXhvaVExQVVJWnhpYjEyb3NOVHJheExOYmsyLU5famxjRnRWdS1TSDJLWjZNUmtEa3RLNkZxaGVtYWNPSmFLSFJnNktJWDVHSk9DVFlmVVdLLWRmWHdiR19LZXpWZm9MWlU4VkVOOGp0QktVX3ZmdWtiZ25BSS05SzVqaEtacm…

Google News Wed, 15 Jul 2026

Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPS1VUNEZkUldGSmNCQkFjT2EtcFBXcWk5TWNtU01EUVV5NFAtRGlHaThhQ0ZwTjFyblV0cWJObllFX2dYX1BleDlUcWw3TDg3VUpCTHVIcnA3RXJNSDVCWmNMQ3EtdGVycDdSbTd1X3NtcGY4ei1yQWhsOW5IM2xiWi1Nc1cxbFd0NENwSU…

Google News Wed, 15 Jul 2026

Vertex Pharmaceuticals Stock 6-Day Losing Spree: Stock Falls 10% - Trefis

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxObTFRckp5QXl4WlhtOGRUZGpfMWZNZjlSdngxOEEtdFA2T3NFSE0zVXE4MWR6dU1PQWlLc3IzQ3JSbFFSWkVRNlpjOG04ay11d1Y0WHo4SUhiQXhoejgwdVR4bWVzNFJ1Z0NOQW9pS1VCTkpaMmMyeWllcUdBMHBRbF9VOEhGZ1FVWVBBMl…

Google News Sun, 21 Jun 2026

3 of Wall Street’s Favorite Stocks to Consider Right Now - StockStory

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPOXB4LUI4TzhHSkFvX2ZCSmhJc1d0c3ZtZVAyN3BOb2pqWWlCOXRYcnd0eVVITC1TazRiWlVvV3Q2SWxYMUxJWEZ3OFZSTlJXa2EyV2NwRk9fbmNDWjh0Z0VBMVh1Y2YyT2ZGU2g4OS1sUkJHYm0ySjF2dWVfUGlJT1NuSWl4cmZKUjhJNE…

Google News Mon, 13 Jul 2026

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOFZFb3RlYmMwclN3cWRoemlYLWo1bnBIOTFSUVdwT3MtczdCR3o0bGVtejd5Q1VHQjJNWjVXWkNlMFZ4OUFXanpucUdCekY2R3dtUzhEOEZlNWVXNjM3U1liQmNUNWFDdFJaVVVqcDROMHJjU29WNXZFZExJR3B0S2ozVXVtX2VmNUk5Vk…

VRTX — Frequently Asked Questions

What is the current share price of Vertex Pharmaceuticals Incorporated (VRTX)?

As of 2026-07-15 16:51 PDT, Vertex Pharmaceuticals Incorporated (VRTX) trades at $477.08 on NasdaqGS. Its 52-week range is $366.54 to $529.59.

What is the market capitalisation of VRTX?

Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $121.09B on NasdaqGS.

What is the P/E ratio of VRTX?

VRTX trades at a trailing price-to-earnings (P/E) ratio of 28.33. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 6.92.

What is the return on equity (ROE) of VRTX?

VRTX has a return on equity (ROE) of 24.20%. Its return on capital employed (ROCE) is 21.38%.

Is VRTX a good stock to buy?

This page provides a data-driven analysis of Vertex Pharmaceuticals Incorporated (VRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space